NCT02155881View on ClinicalTrials.gov

Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia

PHASE3CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Ciclesonide

Ciclesonide nasal spray 50 mcg/actuation

DRUG

Ciclesonide Placebo

Ciclesonide placebo-matching nasal spray

Trial Locations (5)

Unknown

Kazan'

Krasnodar

Moscow

Saratov

Stavropol

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT02155881 - Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia | Biotech Hunter | Biotech Hunter